Urethane-induced somatostatin mediated inhibition of gastric acid: reversal by the somatostatin 2 receptor antagonist, PRL-2903.
Urethane increases the release of somatostatin (SRIF) which inhibits gastric acid secretion. The SRIF monoclonal antibody, CURE.S6 and the novel sst2 antagonist, PRL-2903 injected intravenously at maximal effective doses increased gastric acid secretion by 2 and 10 fold respectively from basal values within 30 min in urethane-anesthetized rats. Plasma gastrin levels were elevated 2.5 fold within 15 min by PRL-2903 (1.3 micromol/kg, i.v.). These data indicate that the low gastrin and acid secretion levels induced by urethane result from endogenous SRIF acting on sst2 and that PRL-2903 is a valuable SRIF antagonist to assess sst2 mediated events.
Kawakubo
K
K
CURE: Digestive Diseases Research Center, VA Medical Center West Los Angeles, and Department of Medicine, UCLA, CA 90073, USA.
Coy
D H
DH
Walsh
J H
JH
Taché
Y
Y
D018686:Anesthetics, Intravenous / Q000008:administration & dosage*; D000818:Animals; D000911:Antibodies, Monoclonal; D005744:Gastric Acid / Q000378:metabolism*; D005753:Gastric Mucosa / Q000187:drug effects* / Q000378:metabolism; D005755:Gastrins / Q000097:blood; D008297:Male; D010456:Peptides, Cyclic / Q000494:pharmacology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D017481:Receptors, Somatostatin / Q000037:antagonists & inhibitors*; D013004:Somatostatin / Q000378:metabolism*; D014520:Urethane / Q000008:administration & dosage*
D018686:Anesthetics, Intravenous; D000911:Antibodies, Monoclonal; D005755:Gastrins; C121568:PRL 2903; D010456:Peptides, Cyclic; D017481:Receptors, Somatostatin; D014520:Urethane; D013004:Somatostatin; C093733:somatostatin receptor 2